Key Principles and Recommended Regimens for First-line Antiretroviral Therapy

  • Author: Paul E. Sax, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 2/20/19 (What's New)

Summary

    Raltegravir vs Efavirenz in Treatment-Naive Patients
    • The phase III STARTMRK trial compared raltegravir with efavirenz, both with emtricitabine/tenofovir DF, in 563 treatment-naive patients
    • At Week 48, the efficacy of raltegravir was noninferior to that of efavirenz, with 86% and 82%, respectively, achieving HIV-1 RNA < 50 copies/mL by intent-to-treat, noncompleter-equals-failure analysis[Lennox 2009]
    • At Week 240, raltegravir was superior to efavirenz with 71% and 61% of patients, respectively, achieving HIV-1 RNA < 50 copies/mL
      Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Coformulated Regimen vs Efavirenz in Treatment-Naive Patients
        Dolutegravir vs Efavirenz in Treatment-Naive Patients
          Considerations for Choosing Efavirenz vs INSTI-based Therapy

          Action required

          Keywords: Initial Antiretroviral Therapy

          ©2018 Clinical Care Options, LLC. All Rights Reserved.

          The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.